Immunotech Biopharm (永泰生物) IPO: Challenges for Cellular Immunotherapies
Immunotech Biopharma, a leading cellular immunotherapy company in China, aims to raise USD 100 to 200 million via a Hong Kong listing. In this...
943 Views
India Generic Drugs: Antitrust Suit Could Cost Billions
This Insight builds on our previous Insight, India Generic Drugs: US Antitrust Inquiry Widens by discussing estimated potential liabilities and...
894 Views
Global Equity Strategy:Â Cautious Outlook Intact; Defensive Sectors Remain Leadership
Global equities (MSCI ACWI) are testing 52-week lows as prices have been consolidating over the last 1-2 months. Our outlook for global equities...
655 Views
Biosimilar Battlefield Update: It's Getting Uglier
A confluence of negative news is causing sharp declines (or trading suspensions) in the share prices of Samsung Biologics Co., (207940...
786 Views
Morningstar Management Behind the Moat 2018:Â Conference Highlights
Morningstar and PitchBook hosted the 10th annual Management Behind the Moat Conference in Chicago on Nov. 7 and 8, offering our institutional...
823 Views